AU2018334214A1 - A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof - Google Patents

A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof Download PDF

Info

Publication number
AU2018334214A1
AU2018334214A1 AU2018334214A AU2018334214A AU2018334214A1 AU 2018334214 A1 AU2018334214 A1 AU 2018334214A1 AU 2018334214 A AU2018334214 A AU 2018334214A AU 2018334214 A AU2018334214 A AU 2018334214A AU 2018334214 A1 AU2018334214 A1 AU 2018334214A1
Authority
AU
Australia
Prior art keywords
compound
sleep
subject
administered
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018334214A
Other languages
English (en)
Inventor
James J. Doherty
Jeffrey M. Jonas
Stephen Jay Kanes
Inderjit KAUL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AU2018334214A1 publication Critical patent/AU2018334214A1/en
Priority to AU2024205601A priority Critical patent/AU2024205601A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018334214A 2017-09-14 2018-09-14 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof Abandoned AU2018334214A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205601A AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US62/558,703 2017-09-14
US201862624678P 2018-01-31 2018-01-31
US201862624680P 2018-01-31 2018-01-31
US62/624,678 2018-01-31
US62/624,680 2018-01-31
US201862653189P 2018-04-05 2018-04-05
US62/653,189 2018-04-05
PCT/US2018/051048 WO2019055764A1 (en) 2017-09-14 2018-09-14 C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205601A Division AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Publications (1)

Publication Number Publication Date
AU2018334214A1 true AU2018334214A1 (en) 2020-03-26

Family

ID=65723895

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018334214A Abandoned AU2018334214A1 (en) 2017-09-14 2018-09-14 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AU2024205601A Pending AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205601A Pending AU2024205601A1 (en) 2017-09-14 2024-08-07 A 19-Nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof.

Country Status (9)

Country Link
US (3) US20220110949A1 (https=)
EP (3) EP4218767A1 (https=)
JP (3) JP2020534270A (https=)
AU (2) AU2018334214A1 (https=)
CA (1) CA3075872A1 (https=)
IL (2) IL303083A (https=)
MX (3) MX2020002889A (https=)
TW (2) TW202339764A (https=)
WO (1) WO2019055764A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
KR20220112803A (ko) * 2019-12-05 2022-08-11 세이지 테라퓨틱스, 인크. 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) * 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
EP3504189A1 (en) * 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE

Also Published As

Publication number Publication date
MX2023010063A (es) 2023-09-06
JP2023038310A (ja) 2023-03-16
WO2019055764A1 (en) 2019-03-21
TW202339764A (zh) 2023-10-16
IL303083A (en) 2023-07-01
US20230201224A1 (en) 2023-06-29
AU2024205601A1 (en) 2024-08-29
CA3075872A1 (en) 2019-03-21
EP4696301A3 (en) 2026-04-29
EP4218767A1 (en) 2023-08-02
US20250387414A1 (en) 2025-12-25
EP3681510A1 (en) 2020-07-22
MX2020002889A (es) 2020-10-01
MX2023010064A (es) 2023-09-06
JP2024107137A (ja) 2024-08-08
JP2020534270A (ja) 2020-11-26
US20220110949A1 (en) 2022-04-14
TW201919642A (zh) 2019-06-01
IL273126A (en) 2020-04-30
EP4696301A2 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
US20250387414A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AU2015336463B2 (en) Compositions and methods for treating insomnia
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
RU2718906C2 (ru) Способы и композиции для лечения гипергидроза
TW202116314A (zh) T型鈣離子通道調節劑之調配物及其使用方法
KR20230018384A (ko) T-형 칼슘 채널 조정제의 사용 방법
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
HK40096830A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20220027981A (ko) 수면 문제를 치료하기 위한 렘보렉산트
US20250375380A1 (en) High strength single unit dose formulations and methods of use thereof
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
JP2026512649A (ja) 疼痛の治療用化合物
EP3989976A1 (en) Lemborexant for treating sleep issues
EP4673123A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
WO2020263253A1 (en) Lemborexant for treating sleep issues

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted